Please login to the form below
Norway
This page shows the latest Norway news and features for those working in and with pharma, biotech and healthcare.
Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma
The CHMP’s recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 27 EU member states, as well as Norway,
Latest news
-
UK rejoins Horizon Europe research initiative under new bespoke agreement
taxpayers.". As part of the agreement, UK scientists will gain access to the world’s largest research collaboration programme, Horizon Europe, and cooperation will be opened up with the EU, Norway,
-
EC approves Atara and Pierre Fabre’s Ebvallo as monotherapy for Epstein-Barr patients
applicable to all 27 EU member states plus Iceland, Norway and Liechtenstein.
-
MHRA approves LEO Pharma’s Adtralza for adolescent patients with atopic dermatitis
Norway and Liechtenstein.
-
Gilead’s Biktarvy received EC approval for the treatment of HIV in paediatric populations
The authorisation is the first paediatric approval for Biktarvy in the EU and applies to all 27 member states, as well as Norway, Iceland and Liechtenstein.
-
BeiGene’s Brukinsa receives EC approval for marginal zone lymphoma
The approval, which is applicable to all 27 member states of the EU, plus Iceland and Norway, follows a positive opinion granted in September by the Committee for Medicinal Products for
More from news
Approximately 1 fully matching, plus 147 partially matching documents found.
Latest Intelligence
-
Piloting a route to the biosimilars opportunities in Europe
Most biosimilar products are introduced into markets through tenders. We have seen discounts of 85% in Norway and 45% in France, following local negotiations.
-
Developing a COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI), an Oslo, Norway-based nonprofit, is helping to coordinate the development of a COVID-19 vaccine and is leading the efforts to finance the
-
Will biosimilars ever catch on in the US?
Notably the biosimilar Renflexis (infliximab-abda) achieved a 70-80% price reduction to its reference product in both Norway and Denmark.
-
The case for a second Brexit referendum: “We need the informed consent of the people”
As many in the pharma industry know, the EEA allows Norway, Iceland and Liechtenstein to be part of the EMA and gain access to the new medicines at the same time.
-
The tipping point
National policy mandates to switch from the originator to biosimilars, as has been the case in Norway, have resulted in rapid and almost complete biosimilar market penetration.
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest appointments
-
Gilead Sciences appoints general manager, Canada
Brysting was most recently general manager of Gilead Nordics, comprising the company's businesses in Sweden, Norway, Denmark, Finland and Iceland.
-
Targovax appoints chief financial officer
Dr Wiklund joins the Oslo, Norway-based immuno-oncology specialist from Aker Biomarine Antarctic, where he served as director of product innovation.
-
Algeta execs join Targovax
Anna-Kirsti Aksnes and Tina Madsen join the firm. Norway's Targovax has added to its senior team with the appointment of two executives from Algeta.
-
Anker Lundemose appointed CEO of Bionor Pharma
The Norway-based biotech, which is focused on peptide-based vaccines for HIV, said Dr Lundemose will take over the role from March 1, when his predecessor Steen Krøyer becomes deputy
-
Matt Regan named AbbVie’s general manager in UK
Was formerly general manager of Abbott in Norway. AbbVie, the new independent biopharma spin-out from Abbott, has appointed Matt Regan as general manager of its UK business. ... Regan was formerly general manager for Abbott in Norway and will now oversee
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
